11,400 Shares in Biogen Inc. $BIIB Purchased by Catalyst Funds Management Pty Ltd

Key Points

• Catalyst Funds Management Pty Ltd bought a new stake in Biogen during the fourth quarter, purchasing 11,400 shares valued at about $2.0 million.
• Biogen continues to attract heavy institutional ownership, with firms like Vanguard, Invesco, AQR, and Pictet increasing their holdings; institutions and hedge funds now own 87.93% of the stock.
• Analysts remain generally constructive despite mixed views: Biogen has a Moderate Buy consensus rating with an average price target of $215.62, while the stock also faces pressure from a failed Parkinson’s trial and related legal scrutiny.

Catalyst Funds Management Pty Ltd purchased a new position in Biogen Inc. (NASDAQ:BIIB - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 11,400 shares of the biotechnology company's stock, valued at approximately $2,006,000.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Biogen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company's stock worth $3,070,514,000 after acquiring an additional 157,857 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company's stock worth $338,731,000 after acquiring an additional 98,001 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Biogen by 30.7% in the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company's stock worth $248,809,000 after acquiring an additional 418,776 shares in the last quarter. Legal & General Group Plc raised its stake in Biogen by 10.1% during the third quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company's stock valued at $223,203,000 after buying an additional 146,583 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its stake in Biogen by 22.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 947,494 shares of the biotechnology company's stock valued at $166,900,000 after buying an additional 176,639 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. HSBC upped their price objective on Biogen from $143.00 to $150.00 and gave the company a "reduce" rating in a research note on Tuesday, March 17th. Citigroup upped their price objective on Biogen from $190.00 to $200.00 and gave the company a "neutral" rating in a research note on Friday, May 1st. Wedbush upped their price objective on Biogen from $191.00 to $196.00 and gave the company a "neutral" rating in a research note on Thursday, April 30th. Tudor Pickering set a $201.00 price objective on Biogen in a research note on Monday, February 9th. Finally, Canaccord Genuity Group upped their price objective on Biogen from $230.00 to $245.00 and gave the company a "buy" rating in a research note on Wednesday, April 1st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $215.62.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s stock may be getting some support from analyst commentary suggesting the recent sell-off could be overdone, with one report saying the trial results were better than first reported and that longer-term optimism remains intact. Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
• Neutral Sentiment: Denali said it will keep running a separate Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant, which preserves some optionality for the broader program but does not offset the failure in idiopathic Parkinson’s disease. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
• Negative Sentiment: The failed Parkinson’s trial has also sparked investor concern and legal scrutiny, with multiple alerts and investigations following the disclosure, adding another overhang to Biogen shares. Investor Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Biogen Stock Up 2.3%

NASDAQ:BIIB opened at $193.76 on Friday. The firm has a market capitalization of $28.61 billion, a PE ratio of 20.79, a price-to-earnings-growth ratio of 1.71 and a beta of 0.19. The stock has a 50 day moving average of $185.48 and a 200-day moving average of $180.75. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business's revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts predict that Biogen Inc. will post 14.18 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.